Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal ³²P or intravenous cyclophosphamide and cisplatin - a Gynecologic Oncology Group study

By Naumann R. Wendel  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 33-34

Informa Healthcare

Access to resources Recommend Favorite

Intraperitoneal -Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

By Berek J.S.   Markman M.   Blessing J.A.   Kucera P.R.   Nelson B.E.   Anderson B.   Hanjani P.  

Gynecologic Oncology, Vol. 74, Iss. 1, 1999-07 ,pp. : 48-52

Elsevier

Access to resources Recommend Favorite

Intraperitoneal Interferon- in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

By Berek J.S.   Markman M.   Stonebraker B.   Lentz S.S.   Adelson M.D.   DeGeest K.   Moore D.  

Gynecologic Oncology, Vol. 75, Iss. 1, 1999-10 ,pp. : 10-14

Elsevier

Access to resources Recommend Favorite

A Phase I Study of Weekly Cisplatin and Whole Abdominal Radiation for the Treatment of Stage III and IV Endometrial Carcinoma: A Gynecologic Oncology Group Pilot Study

By Reisinger S.A.   Asbury R.   Liao S.Y.   Homesley H.D.  

Gynecologic Oncology, Vol. 63, Iss. 3, 1996-12 ,pp. : 299-303

Academic Press

Access to resources Recommend Favorite

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Bookman M.A.   Creasman W.T.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 32-35

Elsevier

Access to resources Recommend Favorite